Cargando…

Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review

This systematic review assessed the long-term outcomes for patients treated with intravitreal antivascular endothelial growth factor or dexamethasone for macular oedema (MO) secondary to retinal vein occlusion (RVO). Studies investigating patients of all ages with MO due to RVO only were included. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, Alexandra, Williams, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198693/
https://www.ncbi.nlm.nih.gov/pubmed/36063388
http://dx.doi.org/10.1136/bmjophth-2022-001010
_version_ 1784727681708851200
author Hunter, Alexandra
Williams, Michael
author_facet Hunter, Alexandra
Williams, Michael
author_sort Hunter, Alexandra
collection PubMed
description This systematic review assessed the long-term outcomes for patients treated with intravitreal antivascular endothelial growth factor or dexamethasone for macular oedema (MO) secondary to retinal vein occlusion (RVO). Studies investigating patients of all ages with MO due to RVO only were included. The review was deliberately broad in scope, including comparative and non-comparative studies to ensure inclusion of real-world type evidence. Risk of bias was assessed. In total, 76 data sets were included (10 775 participants). Overall, mean best-corrected visual acuity (BCVA) improved from baseline to 5 years by 16.1 letters (p<0.01). BCVA improved from baseline in both central RVO (CRVO) and branch RVO (BRVOs) at 2 years, by 9.1 (p<0.01) (difference from baseline in CRVOs) and 9.1 (p<0.01) letters, respectively. At 5 years, BCVA improved from baseline in CRVOs by 15.6 letters and in BRVOs by 16.2; the difference between RVO types was not significant (p=0.18). Two studies had 5-year data for ranibizumab, and improvement was evident. There was no significant difference between outcomes in randomised controlled trials (RCTs) compared with non RCTs. These results suggest a benefit to receiving long-term intravitreal treatments for MO due to RVO.
format Online
Article
Text
id pubmed-9198693
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91986932022-07-08 Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review Hunter, Alexandra Williams, Michael BMJ Open Ophthalmol Review This systematic review assessed the long-term outcomes for patients treated with intravitreal antivascular endothelial growth factor or dexamethasone for macular oedema (MO) secondary to retinal vein occlusion (RVO). Studies investigating patients of all ages with MO due to RVO only were included. The review was deliberately broad in scope, including comparative and non-comparative studies to ensure inclusion of real-world type evidence. Risk of bias was assessed. In total, 76 data sets were included (10 775 participants). Overall, mean best-corrected visual acuity (BCVA) improved from baseline to 5 years by 16.1 letters (p<0.01). BCVA improved from baseline in both central RVO (CRVO) and branch RVO (BRVOs) at 2 years, by 9.1 (p<0.01) (difference from baseline in CRVOs) and 9.1 (p<0.01) letters, respectively. At 5 years, BCVA improved from baseline in CRVOs by 15.6 letters and in BRVOs by 16.2; the difference between RVO types was not significant (p=0.18). Two studies had 5-year data for ranibizumab, and improvement was evident. There was no significant difference between outcomes in randomised controlled trials (RCTs) compared with non RCTs. These results suggest a benefit to receiving long-term intravitreal treatments for MO due to RVO. BMJ Publishing Group 2022-06-14 /pmc/articles/PMC9198693/ /pubmed/36063388 http://dx.doi.org/10.1136/bmjophth-2022-001010 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Hunter, Alexandra
Williams, Michael
Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
title Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
title_full Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
title_fullStr Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
title_full_unstemmed Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
title_short Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
title_sort long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198693/
https://www.ncbi.nlm.nih.gov/pubmed/36063388
http://dx.doi.org/10.1136/bmjophth-2022-001010
work_keys_str_mv AT hunteralexandra longtermoutcomesforpatientstreatedformacularoedemasecondarytoretinalveinocclusionasystematicreview
AT williamsmichael longtermoutcomesforpatientstreatedformacularoedemasecondarytoretinalveinocclusionasystematicreview